Showing results (221-230 of 274) with videos related to

Sort By:
Pageof 28
Neuropediatrics|October 16, 2012
Early-onset LBSL: how severe does it get?M E Steenweg, L van Berge, C G M van Berkel, et al.
American Journal of Hematology|January 28, 2023
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choiceVaishali Sanchorawala, Ashutosh D Wechalekar, Kihyun Kim, et al.
JACC. Cardiooncology|February 18, 2026
Atrial Fibrillation Following Autologous Stem Cell Transplantation in Multiple Myeloma: Incidence, Predictors, and Prognostic ImpactOlayiwola Bolaji, Samantha Brown, Brian C Shaffer, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 15, 2018
Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17pSandy W Wong, Ute Hegenbart, Giovanni Palladini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple MyelomaMalin Hultcrantz, Even H Rustad, Venkata Yellapantula, et al.
Molecular Genetics and Metabolism|November 21, 2015
Glutamine and hyperammonemic crises in patients with urea cycle disordersB Lee, G A Diaz, W Rhead, et al.
Blood|June 27, 2023
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trialMorie A Gertz, Adam D Cohen, Raymond L Comenzo, et al.
Transplantation and Cellular Therapy|October 1, 2022
Pilot Trial of Homebound Hematopoietic Cell TransplantationHeather J Landau, Evelyn Orlando, Elizabeth S Rodriguez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 27, 2020
Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple MyelomaAlexandra Gomez-Arteaga, Gunjan L Shah, Raymond E Baser, et al.
Blood Neoplasia|July 12, 2026
CD8+CD38+ T cells identify functional high-risk multiple myeloma after autologous transplant: BMT CTN 0702 correlatesNezar Mehanna, Andriy Derkach, Billel Gasmi, et al.
Pageof 28